Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Results of the authors' acute and subchronic toxicity studies suggest that MnD PDP will be safe at the doses necessary for clinical imaging; at 10 mumol/kg, the safety factor for MnDPDP is significantly greater than the safety factors of Gd-DTPA (ie, 60-100).
Formulation Development and Antitumor Activity of a Filter-Sterilizable Emulsion of Paclitaxel
QW8184, a stable sub-micron o/w emulsion of paclitaxel has been developed that can be filter-sterilized and administered i.v. as a bolus dose and exhibited reduced toxicity and improved efficacy most likely due to the composition and dependent physicochemical characteristics of the emulsion.
Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
- E. Harpur, D. Worah, P. Hals, E. Holtz, K. Furuhama, H. Nomura
- Medicine, BiologyInvestigative radiology
- 1 March 1993
Gadodiamide injection has been shown to have a remarkably low acute lethal toxicity, superior to that of gadopentetate dimeglumine injection, and had fewer effects on cardiovascular and hemodynamic function after rapid intravenous injection in anesthetized dogs and, in vitro at high concentrations, on erythrocyte fragility and arterial wall tension.
Human pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas chromatography.
Metal ion release from paramagnetic chelates: What is tolerable?
At the currently administered clinical doses, paramagnetic metal chelate complexes presently used as MR contrast enhancement agents appear to be relatively nontoxic and any released manganese is likely to be quickly and efficiently cleared through the liver.
A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
- M. VanWagoner, M. O'Toole, D. Worah, P. Leese, S. Quay
- MedicineInvestigative radiology
- 1 November 1991
Gadodiamide was excreted unmetabolized in the urine with greater than 95% recovery at 72 hours after administration and the serum elimination half-life was approximately 70 minutes.
Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
The safety, tolerance, and pharmacokinetics of gadodiamide injection were evaluated in an open, ascending-dose study in 20 healthy male volunteers and there were no clinically significant changes in laboratory parameters, but minor transient elevations in serum iron were detected.
Association of Escherichia coli lac repressor with poly[d(A-T)] monitored with 8-anilino-1-napthalenesulfonate.
The association of lac repressor with poly[d(A-T)] was monitored with the fluorescent prob 8-anilino-1-naphthalenesulfonate (Ans) and removal of the amino-terminal regions from the repressor decreased the fluorescence from bound Ans by 77%.
Acute myocardial ischemia: MR imaging with Mn-TP.
With T1-weighted MR imaging, Mn-TP showed a potential for delineating the jeopardized area after acute myocardial ischemia, leading to a marked contrast between the two tissue zones.